MannKind announced that it has fully enrolled 305 patients living with type 1 or type 2 diabetes in its INHALE-1 study assessing efficacy and safety of inhaled insulin in the pediatric population. “We are excited to reach this milestone in exploring the potential of Afrezza for a younger generation living with diabetes,” said Dr. Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation. “We expect to complete a primary endpoint analysis in the fourth quarter.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNKD:
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
- MannKind and Sagard Healthcare sign royalty purchase agreement for up to $200M
- MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
- MannKind enters into 7th amendment to supply pact with Amphastar
